Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm tempted to bet you on that but my brother just brought me the equivalent of 13 bottles of bourbon (3- 1.75's and 6-750's.) and I'm running out of bar space, LOL.
At this point, with the ruling from the judge in Kansas expected any day now, it certainly makes sense to correct the share count/structure after they know if they owe any to L2 and SBI.
True, but it seems like paying <$0.02/share for something going for $0.12/share is a decent incentive. I'm guessing that Innova is being flexible and trying to get the deal across the finish line.
2nd app now at 1+ download.
We know of at least $15M heading this way.
Innova (via T&T) has contracts with NHS. QMC (via T&T) does not.
NHS offers an app and it hasn't appeared that any of the previous Innova test kit sales or deals included the QMC app as a bundled offering. And whether it was or wasn't, the press release appears to be that T&T is distributing the QMC product independently from Innova; maybe for use with other's kits.
The twice a week thing is recent, though we had to figure the U.K. needed to do something with their inventory. The relationship between Innova and T&T as their agent/distributor/rep in the U.K is not new.
I don't see anything new here. Isn't this all old info?
How long will the coronavirus vaccines protect you? Experts weigh in.
https://www.washingtonpost.com/lifestyle/2021/03/29/how-long-immunity-lasts-covid-vaccine/
"Looking at studies on natural immunity from the coronavirus, experts hypothesize that protective immunity from the vaccines will last at least six to eight months."
“I think this coronavirus is going to become like other seasonal coronaviruses in that you will either be vaccinated or infected as a child, have a mild illness and then when you see it as an adult, you’re going to have some immunity. While it’s not going to protect you from getting infected, the worst you’ll get is a bad cold,”
Yup, 10 years prematurely puffing up one's chest and celebrating things that never end up happening is a real drag on credibility. Maybe it's best to wait for confirmation. No one consciously wants to look like a fool, right?
Based on the contracts, I'd guess the odds are pretty good that they are Innova's. Whether they include the QDX HealthID app... another story.
BTW, just noticed two different apps pop up in my Play Store:
- one released on July 10, 2020 and last updated on February 17, 2021 with 100+ downloads, and
- a second, released on March 31, 2021 and last updated on March 18, 2021 with 0+ downloads.
- Both are Version 1.5.0. and 37.94MB.
Regardless, there appears to be some desperation here by Squires' peeps. One day Innova is sold out, the next they could sell in the U.S. Seems like maybe there needs to be some tweaking of the script.
And why would anyone care if Innova sells their capacity in the U.S. or overseas? The U.S. is jabbing over 4M a day and climbing. Testing is a tool in the tool box but the vaccine is weapon that is going to put down the virus. As the article says, "To suppress infections, testing must go hand-in-hand with community public health led contact tracing to find cases and must be backed up by decent financial support. People who are sick with COVID are still forced to choose between self-isolation or feeding their families." Unless the government starts paying the bills, less fortunate folks aren't going to isolate. And the fact that the Innova test misses 4 of 10 positives is still a problem.
Yup. With no customers and no commercial products QMC could have processed lots of raw materials through the reactors and right into hazardous waste drums. But the reactors would have been humming, right?
"...where audience members will be tested for Covid before and after the show." Not sure the "after" test is gonna reduce the spread much. ??
Oh well, I guess when you've already paid for tests, you might as well find uses for them.
By definition, Longs are not in and out of this stock. In fact, check the history, "never sold a share" has been a badge of purity.
Yes, an average of 57.5% in sensitivity is obviously mediocre compared to the tests in the 70's and above.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013705.pub2/full#.YFtJfEPMh-E.twitter
I'm not following your point. Whether there is a buyer for mediocre is irrelevant to how something performances.
And pointing out that there are buyers/demand for low priced counterfeit products, wasn't done to discredit QMC's efforts, it was just stating a fact. Google it. As long as there is demand, someone will provide the supply.
The price doesn't make it mediocre, the sensitivity does. The low price just helps offset the middling performance.
I posted a link to the sensitivity measurements for a bunch of tests and Innova's certainly fall into the mediocre bucket. Cheaper is the variable they achieved.
I am going to get whiplash from the back and forth (opposing) claims of:
- Innova being sold out and not needing the U.S.
vs.
- Innova has the capacity and FDA approval is a BFD.
I don't know. I think I'm kinda fine with the soothsayers of a global pandemic, the QMC pivot to AC software, and the later pivot to life science saying, "I told you so!"
At today's price, Pasaca got quite the discount:
$0.125/share X O/S 701,569,276 = Market Cap $87.7M X 51% = $44.7M
$44.7M - $15M = $29.5M / $44.7 = 66%
Q1. Anyone with common sense.
Q2. Revenues from consulting services. (Remember the millions of $'s Art said there would by the end of 2019?)
The next 10-K is gonna force us to revisit LOC talk, isn't it?
And as predicted, the Tech City folks bought a license to a solar technology that doesn't exist and the opportunity to develop products they in return just hand the rights back over to the licensor, LOL.
Yes, when I referred to financials, I meant the very late earlier ones. While I do not believe there are going to be huge revenues reported as part of last year's Innova UK contracts (like Art claimed for months last year), there'll probably be some modest licensing numbers and maybe $'s from the two reactor that were said to have been sold to India.
My perception has been and continues to be that if the financials were going to have a positive impact on the share price they would have been filed earlier.
Is this a faux threshold breach like the split second, one trade $0.20 target?
My interpretation is that parsing this is a mistake, LOL.
As a follow-up, the estimated number of shares at 51% was 935M.
So...
$15M/935 shares = $0.016/share
(See #97551)
They will receive common stock from QMC in the quantity that equates to getting their total to 51%. The price for those shares has already been determined to be $10,500,000. Ted has previously estimated what that number needs to be and, if I remember correctly, based on that estimate the $/share comes in under 2 cents.
I would say that one refers to what they are buying and the other where they are buying.
FYI, it does not say in the 10-K that "Pasaca will then buy shares on the open market to obtain 51% control."
It says:
From OTCMarkets:
Outstanding Shares
701,569,276
03/29/2021
Up another 2,229,880 from the 10-K
About a month old but I don't recall reading that the FDA turned down Innova twice previously:
Diagnostic developers hedge on coronavirus rapid antigen tests, citing conflicting FDA messages
Actually, it appears the 911,542,857 GBP was spread among 5 suppliers:
(From https://bidstats.uk/)
Weren't we told that Dr. Malan was working on a quantitative test. He now works for Innova.